Rx-360 Summary of the The European Commission's Recently Issued Two Final Guidances in Support of the EU Falsified Medicines Directive
The European Commission has recently issued two final guidances in support of the EU Falsified Medicines Directive.
The Guidelines on the Formalised Risk Assessment for Ascertaining the Appropriate Good Manufacturing Practice for Excipients of Medicinal Products for Human Use indicates that the appropriate GMP for excipients of medicinal products for human use are to be determined on the basis of a formalized risk assessment outlined in the guidelines.
The risk assessment is to take into account requirements under other appropriate quality systems as well as the source and intended use of the excipients and previous instances of quality defects. The MAH should have the risk assessment/management document for appropriate GMP for excipients available on site for review by GBMP inspectors. A risk assessment as set out in these guidelines should be carried out for excipients for authorized medicinal products for human use by 21 March 2016.
The Guidelines on Principles of Good Distribution Practice GDP of Active Substances for Medicinal Products for Human Use follow the same principles that underlie the guidelines of EudraLex Volume 4, Part II, Chapter 17, with regard to the distribution of active substances and the Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use. These guidelines provide stand-alone guidance of GDP for importers and distributors of active substances for medicinal products for human use. These guidelines do not apply to intermediates of active substances. Distributors of active substances for medicinal products for human use should follow these guidelines as of 21 September 2015.
To View or Download the Guidance on Risk Assessments for Excipients, Click Here
To View or Download the Guidance on GDP for APIs, Click Here
To View or Download the Rx-360 Summaries of the Guidances, Click Here
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance